ArticleMalaria journal2026
Preparation, characterization and pre-clinical evaluation of artemether-lumefantrine-paracetamol (AL-P) loaded nanocarriers in the treatment of malaria.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria remains a pertinent global health burden. Current artemether-lumefantrine (AL) therapy is limited by low bioavailability and drug resistance, necessitating new approaches. Solid lipid nanoparticles (SLNs) offer a promising delivery system to mitigate these issues. This study investigates SLNs for the co-delivery of AL and paracetamol to enhance the efficacy and safety of this anti-malarial regimen.
methodSolid lipid nanoparticles co-loaded with artemether, lumefantrine, and paracetamol were produced using melt-emulsion ultrasonication and analyzed using dynamic light scattering, transmission electron microscopy, and ultraviolet-visible spectroscopy. Antiplasmodial activity was established in a Plasmodium berghei-infected mouse model using daily dosing and a single 2 mg/kg dose. Parasitemia, survival, and toxicity by histology and biochemistry were quantified.
resultsOptimized ALP-SLNs had desirable physicochemical properties, including a particle size of 187.6 ± 3.2 nm, PDI of 0.142, and a zeta potential of - 50.1 ± 1.4 mV, and TEM micrographs confirmed spherical shape. Encapsulation efficiencies were > 88% (ART: 88.79%, LUM: 99.19%, PAR: 99.85%), and loading capacities were ART: 12.4%, LUM: 11.8%, PAR: 13.1%. In vivo antiplasmodial tests for activity against Plasmodium berghei ANKA in Swiss Albino mice exhibited > 95% chemosuppression (95.67%) and 100% day-60 survival with ALP-SLNs, surpassing free drugs and placebo nanoparticles. Toxicity studies in pre-clinical experiments showed normal parameters, except for one mouse that developed a pulmonary lesion.
conclusionALP SLNs demonstrated favorable physicochemical properties, a satisfactory safety profile in acute and sub-acute preclinical testing, and superior antiplasmodial efficacy and a highly effective delivery system for malaria triple therapy compared to free drugs. These findings highlight their potential in overcoming malaria treatment challenges, hence supporting further pharmacokinetic and translational studies toward clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.